Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / FEMY - Femasys' FemCerv tissue sampler for cervical cancer diagnosis receives product approval in Canada stock rises 10%

FEMY - Femasys' FemCerv tissue sampler for cervical cancer diagnosis receives product approval in Canada stock rises 10%

Femasys Inc.

2023-05-03 09:14:05 ET

  • Femasys' ( NASDAQ: FEMY ) endocervical tissue sampler FemCerv received product approval from Health Canada and the Public Health Agency of Canada.
  • FEMY is up ~10% before the bell.
  • FemCerv is designed to collect and contain a comprehensive sample to maximize quality and quantity.
  • FemCerv captures tissue sample with minimal pain and has the potential to improve the standard of care for diagnosing cervical cancer.
  • FemCerv is designed to be used with colposcopy and capture a comprehensive 360-degree tissue sample in a pain-free office visit, maximizing quality and quantity.
  • Press Release

For further details see:

Femasys' FemCerv tissue sampler for cervical cancer diagnosis receives product approval in Canada, stock rises 10%
Stock Information
Company Name: Femasys Inc.
Stock Symbol: FEMY
Market: NASDAQ
Website: femasys.com
Menu
FEMY FEMY Quote FEMY Short FEMY News FEMY Articles FEMY Message Board
Get FEMY Alerts

News, Short Squeeze, Breakout and More Instantly...